New injection shows promise for untreatable liver cancer

NCT ID NCT06310590

First seen Feb 03, 2026 · Last updated May 08, 2026 · Updated 14 times

Summary

This early-stage study tested a new drug called NRT6003 in 40 adults with liver cancer that cannot be surgically removed. The main goals were to check for side effects and see if the injection shrinks tumors in the liver. Researchers also measured how long the tumors stayed controlled. This is a first step to see if the treatment is safe enough for larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhongda Hospital, Southeast University

    Nanjing, Jiangsu, 210009, China

  • Zhongshan Hospital, Fudan University

    Shanghai, China

Conditions

Explore the condition pages connected to this study.